Health Trials

Intravital Microscopy in Human Solid Tumors

ConditionsSolid Tumor, AdultClinical Stage IV Gastric Cancer AJCC v8Malignant Solid NeoplasmMetastatic Colorectal CarcinomaMetastatic Gastric CarcinomaMetastatic Primary Malignant Brain NeoplasmMetastatic SarcomaPostneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8Resectable Colorectal CarcinomaResectable Liver and Intrahepatic Bile Duct CarcinomaResectable Pancreatic CarcinomaResectable SarcomaStage IV Colorectal Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Brain NeoplasmMetastatic Breast CarcinomaMetastatic Liver CarcinomaMetastatic Pancreatic CarcinomaResectable Brain NeoplasmResectable Breast CarcinomaResectable Gastric CarcinomaStage IV Hepatocellular Carcinoma AJCC v8Stage IV Pancreatic Cancer AJCC v8
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMayo Clinic

About this trial

This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated with solid tumors. The IVM observations may determine if an individual patient's tumor vessels would be amenable to receiving systemic therapy, based on the functionality of the vessels.

Eligibility criteria

Qualifiers

Age ≥ 18 years of age

Eastern Cooperative Oncology Group (ECOG)Performance Status of ≤ 2

Measurable tumor by direct visualization requiring surgical resection in the operating room (OR)

Tumor types of origin include gastric, pancreatic, hepatobiliary, colorectal, sarcoma, brain, or breast cancer that may involve the axillary lymph nodes cancers. Tumors may be primary or metastatic

Disqualifiers

Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations

Renal dysfunction as defined as a glomerular filtration rate (GFR) < 45

Liver dysfunction as defined by Child-Pugh score > 5, or liver function test (LFT)'s 1.5 x above normal range

Any known allergy or prior reaction to fluorescein or a positive skin prick test to fluorescein

Trial design

Treatments tested in this trial

  • Diagnostic Microscopy
  • Fluorescein Sodium Injection

Treatment groups

85 Participants
are divided into 1 treatment group

Sponsors and collaborators

Mayo Clinic

Lead sponsor

Source ClinicalTrials.gov